PT  - JOURNAL ARTICLE
AU  - Montgomery, Austin
AU  - Tsiatsianis, Georgios Christos
AU  - Mouratidis, Ioannis
AU  - Chan, Candace S.Y.
AU  - Athanasiou, Maria
AU  - Papanastasiou, Anastasios D.
AU  - Kantere, Verena
AU  - Vathiotis, Ioannis
AU  - Syrigos, Konstantinos
AU  - Yee, Nelson S.
AU  - Georgakopoulos-Soares, Ilias
TI  - Utilizing nullomers in cell-free RNA for early cancer detection
AID  - 10.1101/2023.06.10.23291228
DP  - 2023 Jan 01
TA  - medRxiv
PG  - 2023.06.10.23291228
4099  - http://medrxiv.org/content/early/2023/06/16/2023.06.10.23291228.short
4100  - http://medrxiv.org/content/early/2023/06/16/2023.06.10.23291228.full
AB  - Early detection of cancer can significantly improve patient outcomes; however, sensitive and highly specific biomarkers for cancer detection are currently missing. Nullomers are short sequences that are absent from the human genome but can resurface due to somatic mutations in cancer. We examine over 10,000 whole exome sequencing matched tumor-normal samples to characterize nullomer resurfacing across exonic regions of the genome. We identify nullomer resurfacing mutational hotspots within tumor genes and report that certain mutational signatures are associated with nullomer resurfacing. We show that DNA mismatch repair and homologous recombination repair can be detected from the nullomer profile and provide evidence that nullomers can be used to identify neoepitopes and other targets for precision oncology. Finally, we provide evidence for the identification of nullomers in cell free RNA from peripheral blood samples, enabling early detection of multiple tumor types. We show multiple tumor classification models with an AUC greater than 0.9, including a hepatocellular carcinoma classifier with an AUC greater than 0.99.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was funded by the startup funds of I.G.S. from the Penn State College of Medicine.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Source data were openly available before the initiation of the study. Liquid biopsy cfRNA fastq files were downloaded from (Zhu et al. 2021; S. Chen et al. 2022).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesThe code for this work can be found at: https://github.com/Georgakopoulos-Soares-lab/cfRNA-nullomer-analysis https://github.com/Georgakopoulos-Soares-lab/cfRNA-nullomer-analysis